Clinical Trials · us
Hopes for Longer Survival Set Back: Geron Terminates Phase 3 Imetelstat Trial in Myelofibrosis
An independent monitoring committee concluded that the 327-patient trial was unlikely to demonstrate an overall survival benefit, prompting Geron to stop it early. Full efficacy data have not yet been released, and no new safety signals have been identified that change the existing understanding of risk.
For patients with myelofibrosis who relapse after receiving JAK inhibitors or whose treatment is ineffective, extending life is a key question that new therapies must address. On October 28, Geron announced the termination of IMpactMF, its Phase 3 trial evaluating imetelstat: an independent data monitoring committee concluded that the study was unlikely to meet its primary endpoint of overall survival.
The study, registered as NCT04576156, enrolled 327 patients, all with intermediate-2 or high-risk disease. OncLive added that participants also had to be ineligible for allogeneic hematopoietic stem cell transplantation. The study targeted patients for whom existing drug treatment had failed and transplantation was not an option.
The randomized, open-label trial assigned patients in a two-to-one ratio to receive imetelstat or the best available therapy at the time. Its central question was whether imetelstat could help patients live longer; other assessments covered symptoms, spleen volume, and anemia response. Expectations of a survival benefit are now insufficient to support continuing the trial.
However, the data behind the decision to stop the trial have not yet been disclosed. According to OncLive, efficacy results have not been released, and the company’s announcement did not specify whether the committee’s recommendation arose from a planned interim analysis; primary completion had originally been estimated for 2028. The survival difference between the two groups, the uncertainty around the estimates, and whether any patient subgroups responded differently remain unknown. The trial’s termination therefore cannot be directly interpreted as proof that the drug increases the risk of death.
On safety, Geron said the trial showed no new signals that would change imetelstat’s existing safety profile or require additional monitoring. This is a separate judgment from the insufficient prospects for efficacy, and it does not mean the drug has no known risks. The company will analyze the data further and release the results to the scientific community at a later date, but has not yet provided a specific timeline.
Imetelstat, marketed as Rytelo, is already approved in the United States and the European Union for certain patients with lower-risk myelodysplastic syndromes; the trial being terminated is in myelofibrosis. Treatment evidence has its own scope of applicability across different diseases and patient populations. For this study, the most pressing questions are why the anticipated survival advantage was not supported and what testable leads the full results may offer for future research.